Shionogi Investigational RSV Antiviral Reaches Primary Endpoint for Phase 2 Trial
Yesterday, Shionogi, a Japanese pharmaceutical company, announced its novel investigational respiratory syncytial virus (RSV) oral antiviral candidate, S-337395, achieved its primary endpoint in a phase 2 clinical trial. In the highest dose group of S-337395, there was an 88.94% reduction in viral load (P<0.0001), and also a statistically significant improvement in clinical symptom scores.1 Trial […]
Challenges and Implications of the V Quinn TB Prevention Trial
The V Quinn trial assessed levofloxacin as a preventive treatment for drug-resistant tuberculosis (MDR-TB) in household contacts of MDR-TB patients in Vietnam. A total of 2041 participants were randomized to receive six months of daily levofloxacin or a placebo, with TB incidence as the primary endpoint. The study found no statistically significant difference in TB […]
Will Trump Administration’s Funding Pauses, Withdrawal from WHO Hamper Public Health?
On January 20, the Trump Administration issued an executive order announcing its withdrawal from the World Health Organization (WHO). The order stated it was, “due to the organization’s mishandling of the COVID-19 pandemic that arose out of Wuhan, China, and other global health crises, its failure to adopt urgently needed reforms, and its inability to […]
New study identifies key protein’s role in psoriasis
Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease- and infection-protecting immune cells. In a new study, researchers at Case Western Reserve University School of Medicine have determined that a protein called NF-kB c-Rel can intensify the condition’s symptoms when activated by signals from the […]
Communicable disease threats report, 24-31 January 2025, week 5
Seasonal influenza Seasonal influenza is a preventable infectious disease with mostly respiratory symptoms. It is caused by influenza virus and is easily transmitted, predominantly via the droplet and contact routes and by indirect spread from respiratory secretions on hands etc. Read more Source link
Advancing STOP2030 Treatment in Global Health
The STOP2030 project in northwestern Argentina aims to develop more effective tools for controlling neglected tropical diseases (NTDs), particularly soil-transmitted helminths (STH). The study tests a combination of albendazole and ivermectin, which has shown improved efficacy against several STH species, including those resistant to standard treatments like albendazole and mebendazole. The ultimate goal is to […]
Early Release – National Surveillance of Human Ehrlichiosis Caused by Ehrlichia ewingii, United States, 2013–2021 – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal
Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA (S.N. Adams); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.N. Adams, N.C. […]
Oropouche in Parts of Brazil and Panama – Level 2 – Level 2 – Practice Enhanced Precautions – Travel Health Notices | Travelers’ Health
Oropouche is a disease caused by Oropouche virus. It is spread primarily through the bites of infected biting midges (small flies) and mosquitoes. Oropouche virus has been found in semen. It is unknown if Oropouche can be spread through sex. Symptoms of Oropouche include headache, fever, muscle aches, stiff joints, nausea, vomiting, chills, or sensitivity to […]
DoxyPEP Shows Promise for Reducing STIs in 2 Studies
Amid the ongoing threat of sexually transmitted infections (STIs), doxycycline postexposure prophylaxis (doxyPEP)—a preventive treatment in which individuals take a dose of doxycycline up to 3 days after unprotected sex—could help reduce cases, according to 2 studies published in JAMA Internal Medicine. Source link
